This Week in Biotech: Gilead Sciences, Inc. (GILD), GlaxoSmithKline plc (ADR) (GSK)

Page 1 of 2

With the SPDR S&P Biotech Index up 31% over the trailing-12-month period, it’s evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let’s have a look at some of the rulings, studies, and companies that made waves in the sector last week.

For a second week in a row we were privy to a little bit of everything: FDA panel reviews, new clinical data, detailed FDA updates, buyout rumors, and even snowstorms.

On Monday, Depomed Inc (NASDAQ:DEPO) announced that the Reproductive Health Drugs Advisory Committee was recommending against the approval of its hot-flash drug, Sefelsa, with 12 of 14 members ushering in a thumbs-down. The negative ruling wasn’t a huge shock, as Sefelsa didn’t meet its primary endpoints in the first two clinical trials and had what I deem an abnormally large number of patients drop out of all three trials. In the meantime, DepoMed plans to completely abandon all spending and research on Sefelsa unless it appears the drug has a good shot at gaining approval. Shares dipped by 9.5% this week.

Gilead Sciences, Inc. (NASDAQ:GILD)Gilead Sciences, Inc. (NASDAQ:GILD) continues to churn out nothing but fantastic news with its experimental oral hepatitis-C drug, Sofosbuvir. In a mid-stage combination trial with Johnson & Johnson (NYSE:JNJ) and Medivir‘s Simeprevir, the combo cleared all detectable levels of the virus in 100% of genotype 1 patients — the most common form of hepatitis-C. With no adverse events reported, Sofosbuvir once again proved to the biotech community that it could be the standalone and combination drug of choice in oral hepatitis-C care.

Pharmaceutical company Impax Laboratories Inc (NASDAQ:IPXL) was crushed on Tuesday, after it provided an update to investors regarding the FDA’s complete response letter on idiopathic Parkinson’s disease drug Rytary. According to the update, the FDA cited 12 points of concern with its Hayward, Calif., facility, of which three were repeat violations from a warning letter sent to the company in 2011. What this means for Impax is longer delays in attempting to rectify these problems and probably another nine months to a year before Rytary goes before the FDA for a third time. Shares fell nearly 17% on the week.

Page 1 of 2

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!